skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells

Original Research

(1632) Views  (344) Full article downloads

Authors: Borhane Annabi, Eric Vaillancourt-Jean, Alexander G Weil, et al

Published Date November 2010 Volume 2010:3 Pages 219 - 226
DOI: http://dx.doi.org/10.2147/OTT.S14503

Borhane Annabi1,*, Eric Vaillancourt-Jean1,*, Alexander G Weil3, Richard Béliveau2,3
1Laboratoire d’Oncologie Moléculaire, Département de Chimie, Centre de Recherche BioMED, 2Laboratory of Molecular Medicine, Université du Québec à Montréal, Quebec, Canada; 3Department of Neurosurgery, CHUM Notre Dame, Montreal, Quebec, Canada; *These authors contributed equally to this work

Abstract: Targeting of the vascular endothelium compartment explains, in part, the therapeutic efficacy of the nonselective β-adrenergic antagonist propranolol against common endothelial tumors such as hemangiomas. In vitro, the antiangiogenic biological activity of propranolol was shown to inhibit human brain microvascular endothelial cell tubulogenesis. However, possible interference of propranolol with cell signaling associated with the tumoral compartment remains unexplored. We therefore assessed the potency of propranolol against a pediatric brain tumor-derived DAOY medulloblastoma cell model. Gene expression of β1-, β2-, and β3-adrenergic receptors was confirmed in DAOY cells by semiquantitative RT-PCR. We next found that propranolol dose-dependently inhibited induction of the key extracellular matrix-degrading and blood–brain barrier disrupting enzyme matrix metalloproteinase-9 (MMP-9) by phorbol 12-myristate 13-acetate (PMA). Propranolol not only inhibited PMA-induced phosphorylation of the extracellular signal-regulated kinase (Erk), but also that of IkappaB (IκB), preventing the IκB phosphorylation which is a prerequisite for IκB degradation. Propranolol inhibition of IκB phosphorylation was shown to occur with optimal efficacy at 30 µM. Although propranolol, at up to 100 µM, did not affect cell viability, it potentiated PMA-mediated signaling that ultimately led to diminished phosphorylation of Akt. The anti-Erk and anti-Akt phosphorylation effects are both suggestive of antiproliferative and antisurvival signaling, respectively. Our data are therefore indicative of a pharmacological role for propranolol against β-adrenergic receptor signaling functions involving the nuclear factor-kappaB-mediated regulation of MMP-9.

Keywords: medulloblastoma, β-adrenergic receptors, MMP-9, NF-κB




 

Other articles by Dr Borhane Annabi



Readers of this article also read:

Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Methemoglobinemia due to topical pharyngeal anesthesia during endoscopic procedures
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Management of achalasia
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Study of pharmacokinetics and tissue distribution of liposomal brucine for dermal administration
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Ruxolitinib for the treatment of myelofibrosis: its clinical potential